We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nanostics Prostate Diagnostic Improves Prediction of Prostate Cancer
The item has been added to your shopping cart.
Nanostics Prostate Diagnostic Improves Prediction of Prostate Cancer
Canadian diagnostics company Nanostics released interim trial data showing its ClarityDX prostate test is 147 percent more specific than the prostate-specific antigen (PSA) blood test for predicting clinically significant prostate cancer.